cRGD-Functionalized Nanohybrid Conjugates Codelivering Temozolomide and Rapamycin for Treating Glioblastoma Multiforme: In Vitro and In Vivo Evaluation
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Prabhjeet Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Pilani Campus, Vidya Vihar, Pilani 333 031, Rajasthan, India. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Sirolimus, Peptides, Cyclic. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
The conventional treatment of glioblastoma multiforme primarily uses Temozolomide as a chemoadjuvant alongside debulking surgery and radiotherapy; however, resistance, as well as tumor recurrence, remains a common outcome. Employing combination therapy to target multiple pathways while improving delivery with advanced systems has always been sought after. Herein, we report cRGD-functionalized hybrid polymeric nanoconjugates that could deliver Temozolomide (TMZ) and rapamycin (RAP) (cRGD-Hybrid TMZ/R NCs) as a dual payload. The cRGD-Hybrid TMZ/R NCs were thoroughly characterized, exhibiting a particle size and surface zeta potential of 141.83 nm (PDI 0.233) and -0.168 mV, respectively. The nanoconjugates carrying TMZ and RAP as dual payloads were initially screened for synergism by determining their combination index in C6 and U87MG glioma cells. Further, in vitro cell-based assays showed improved cellular uptake, cytotoxicity, and apoptotic potential of hybrid nanoconjugates. Thereafter, the cRGD-Hybrid TMZ/R NCs were evaluated in a C6-cell-induced syngeneic orthotropic glioma model in Sprague-Dawley rats, exhibiting an improved therapeutic outcome including, reduced hemispherical width (RH/LH) ratios, tumor burden, and improved survival rates compared to the free drug(s) counterpart. The histopathological evaluation indicated no major sign of toxicity in vital organs such as heart, lungs, liver, kidney, and spleen, affirming the biocompatibility of the developed cRGD-Hybrid TMZ/R nanoconjugates. In conclusion, amalgamating the cRGD cell-penetrating peptide with polymer hybrid nanoconjugates presents a better approach for delivering multiple payloads in the treatment of GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Pilani Campus, Vidya Vihar, Pilani 333 031, Rajasthan, India.
ORCID-Profile: Anupama Mittal, Deepak Chitkara
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Singh, P., Mittal, A., & Chitkara, D. (2025). cRGD-Functionalized Nanohybrid Conjugates Codelivering Temozolomide and Rapamycin for Treating Glioblastoma Multiforme: In Vitro and In Vivo Evaluation. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00229
Vancouver
Singh P, Mittal A, Chitkara D. cRGD-Functionalized Nanohybrid Conjugates Codelivering Temozolomide and Rapamycin for Treating Glioblastoma Multiforme: In Vitro and In Vivo Evaluation. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00229
BibTeX
@article{Singh2025,
author = {Singh, Prabhjeet and Mittal, Anupama and Chitkara, Deepak},
title = {cRGD-Functionalized Nanohybrid Conjugates Codelivering Temozolomide and Rapamycin for Treating Glioblastoma Multiforme: In Vitro and In Vivo Evaluation},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00229}
}
EUVIMED